Google
IQV — IQVIA HOLDINGS INC (Healthcare >> Diagnostics & Research)
IQV FAQ
What is IQV's P/E ratio?
IQVIA HOLDINGS INC (IQV) currently trades at a P/E ratio of 22.38.
What is IQV's ROE?
IQVIA HOLDINGS INC reports a Return on Equity (ROE) of 22.26%.
What is IQV's dividend yield?
IQVIA HOLDINGS INC offers a dividend yield of 0.00%.
What is IQV's Deepscope Quality Score?
Deepscope rates IQV's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy IQV?
Deepscope's AI Timing Score for IQV is 64 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does IQV belong to?
IQVIA HOLDINGS INC is classified under the Healthcare >> Diagnostics & Research sector on the NYSE exchange.
|
USD 183.45
Price
-3.43
(-1.84%)
Day Change
|
|
|---|
IQV, the overall quality is not quite good ( Quality = 54) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Acceleration of ROE growth rate is below our criteria.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not quite good , financial health is not quite good , and ability to make profit is not quite good , ...
| Quality Factors |
|
52% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 91 |
| Magic Formula Rank by ROA |
1791
|
| Magic Formula Rank by ROE |
1791
|
| Magic Formula Rank by ROIC |
1914
|
| Price | 183.45 |
| PBV / Sector |
4.88 / -23.44
|
| Earning Per Share | 8.20 |
| PE / Sector |
22.38 / 37.86
|
| PEG or PE/Growth / Sector |
1.93 / 1.41
|
| Average 1M Daily Value |
246.49 M
GREAT
|
| Average 1W Daily Value |
229.00 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:34 |
| Symbol | IQV |
| Name | IQVIA HOLDINGS INC |
| Sector | Healthcare >> Diagnostics & Research |
| Market | NYSE |
| Listed Shares | 166.90 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 30,998.34 / 32,142.66 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2400 Ellis Road, Durham, NC, United States, 27703
Phone: 919 998 2000
Website: https://www.iqvia.com
Employees: 93,000
Description: IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
ME vs SECTOR Healthcare >> Diagnostics & Research
Click a bubble to view stock details · Bubble size represents market capitalization share
